Showing results (151-160 of 326) with videos related to

Sort By:
Pageof 33
Thrombosis and Haemostasis|March 8, 2003
Compliance and stability of INR of two oral anticoagulants with different half-lives: a randomised trialSilvy Laporte, Sara Quenet, Andréa Buchmüller-Cordier, et al.
Thrombosis Research|December 5, 2020
Opinion and practice survey about the use of prognostic models in acute pulmonary embolismAntoine Elias, Jeannot Schmidt, Abdelouahab Bellou, et al.
Chest|October 10, 2021
Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism: A Randomized TrialBenjamin Planquette, Laurent Bertoletti, Anaïs Charles-Nelson, et al.
The American Journal of Medicine|April 26, 2020
Evaluation of Venous Thromboembolism Recurrence Scores in an Unprovoked Pulmonary Embolism Population: A Post-hoc Analysis of the PADIS-PE trialLeela Raj, Emilie Presles, Raphael Le Mao, et al.
British Journal of Clinical Pharmacology|November 14, 2018
Effectiveness and safety of 110 or 150 mg dabigatran vs. vitamin K antagonists in nonvalvular atrial fibrillationPatrick Blin, Caroline Dureau-Pournin, Yves Cottin, et al.
Thrombosis and Haemostasis|June 12, 2010
Population pharmacokinetics of fondaparinux administered at prophylactic doses after major orthopaedic surgery in everyday practiceXavier Delavenne, Paul Zufferey, Denis Baylot, et al.
Clinical Pharmacology and Therapeutics|December 1, 2018
Comparative Effectiveness and Safety of Standard or Reduced Dose Dabigatran vs. Rivaroxaban in Nonvalvular Atrial FibrillationPatrick Blin, Caroline Dureau-Pournin, Yves Cottin, et al.
Thrombosis and Haemostasis|November 8, 2008
Analysis of the venous thromboembolic risk associated with severe postpartum haemorrhage in the NOHA First cohortCéline Chauleur, Eva Cochery-Nouvellon, Eric Mercier, et al.
Blood Reviews|May 23, 2019
Indications and potential pitfalls of anticoagulants in pulmonary hypertension: Would DOACs become a better option than VKAs?Victor Margelidon-Cozzolino, Xavier Delavenne, Judith Catella-Chatron, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|June 30, 2019
Comparative Real-Life Effectiveness and Safety of Dabigatran or Rivaroxaban vs. Vitamin K Antagonists: A High-Dimensional Propensity Score Matched New Users Cohort Study in the French National Healthcare Data System SNDSPatrick Blin, Caroline Dureau-Pournin, Jacques Bénichou, et al.
Pageof 33